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ABSTRACT OF THESIS 
 
 
 
 
ORIENTATION-SPECIFIC IMMOBILIZATION OF BMP-2 ON PLGA SCAFFOLDS 
 
A variety of synthetic bone graft materials such as the polymer poly(lactic-co-glycolic 
acid) (PLGA) have been investigated as alternatives to current tissue based bone graft 
materials.  In this study, efforts have been made to improve the tissue-PLGA interface by 
immobilizing bone morphogenetic protein-2 (BMP-2) in an oriented manner on scaffolds 
using covalently immobilized heparin.  The results demonstrated a four-fold increase in 
covalently immobilized heparin compared to non-specific heparin attachment.  
Furthermore, the scaffolds with covalently attached heparin retained approximately three-
fold more BMP-2 than did either scaffolds with no heparin attached or scaffolds with 
non-specific heparin attachment.  The activity of scaffolds with BMP-2 immobilized in 
various manners was examined using an alkaline phosphatase assay on C3H10T1/2-
seeded scaffolds.  These results indicated approximately twice the amount of activity 
with scaffolds that had BMP-2 immobilized with covalently attached heparin than on 
scaffolds with adsorption of BMP-2 and a three-fold increase in activity when compared 
to scaffolds that had non-specific heparin attachment as the mechanism for BMP-2 
immobilization.  These results demonstrated that PLGA with covalently linked heparin 
has potential to immobilize BMP-2 in a specific orientation that is favorable for cell-
receptor binding, leading to the more efficient use of the bone-growth factor.     
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1 INTRODUCTION 
 Bone defects, regardless of whether occurring due to trauma or to disease, that are too 
large to repair on their own typically require bone grafts for the healing process.  One of the 
most popular current bone graft techniques is the use of autografts whereby bone tissue is 
surgically removed from one location on the patient, and then implanted into the defect.  The 
advantage associated with autografts is the compatibility of the tissue.  Because the 
implanted material comes from the host, there is no risk for disease transmission.  However 
this method requires one surgery to harvest the bone tissue and another to implant it at the 
defect site.  Supply and donor site morbidity are also problems associated with autografts. 
 Allografts are another option.  Here the bone tissue comes from same species’ 
donors in the form of demineralized bone matrix particles, or a combination of cancellous 
and cortical bone chips and paste.  Allografts do well at providing a natural tissue matrix 
for bone regeneration, but like autografts, donor tissue can be scarce.  Also, there is a risk 
for disease transmission and the potential for an adverse immune response.   
 Xenografts are yet another option for bone grafts.  With xenografts, the bone 
tissue used in the grafting process is usually bovine or porcine in origin, which could 
address the lack of donor tissue.  However, there is still the risk of disease transmission 
and the added potential for an adverse immune response similar to allograft tissue.    
 Synthetic bone graft substitutes are an option that is growing in popularity.  
Synthetic materials range from ceramics, such as calcium sulfate and calcium phosphate, 
to polymers, such as poly(lactic-co-glycolic) acid (PLGA) and the biopolymer chitosan.  
Synthetics have the potential to provide a virtually unlimited supply of graft material.  
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They also only require one surgery for graft procedure as there is no need to surgically 
remove tissue from a donor site.  Disease transmission would be minimized as well.   
 Another advantage of synthetics as bone graft alternatives is that they can be 
modified to improve biocompatibility.  Growth factors and other biomolecules can be 
immobilized on the biomaterial surface to generate a specific desired response.  For bone 
grafts, the ideal response would be that the implanted material would induce bone 
regeneration such that native bone tissue from the host grows into the defect site.   
 A variety of methods exist to link the growth factors to the polymer.  They can be 
directly adsorbed on the surface or chemically attached at specific locations.  
Alternatively, another compound can be used to link the polymer with the growth factor 
in such a way that the growth factor is oriented in a particular manner.  The advantages of 
chemically attaching the biomolecules to the surface are that stability of binding is 
increased with covalent attachment and the orientation can be better controlled than with 
random adsorption.  The surface density of the biomolecules has potential to be 
controlled using direct chemical attachment as well.  Using a chemical spacer can have 
the same advantages as direct attachment and can reduce steric hindrance of the 
biomolecule by getting it away from the biomaterial surface, potentially increasing its 
effectiveness at generating the desired biological response.   
 Based on the above knowledge, we hypothesized that the oriented attachment of 
the growth factor bone morphogenetic protein 2 (BMP-2) to PLGA scaffolds would lead 
to a better cellular response in vitro than the random adsorption or even random covalent 
immobilization of BMP-2 on the scaffolds.  It is expected that future in vivo studies 
 2
examining oriented growth factor attachment to polymer scaffolds would show a 
regeneration response of the host bone tissue instead of just a repair response.   
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2 BACKGROUND AND SIGNIFICANCE 
2.1 Biomaterials 
 In 2005 there were more than 500,000 bone graft procedures done in the United 
States and 2.2 million done world-wide.[1]  With the aging of the U.S. population one 
can expect those numbers to increase.  Of the different tissue-based bone grafting 
techniques, autografts are considered the gold standard.[1, 2]  However, all have 
disadvantages.  Autografts require one surgery on the same patient to harvest the bone, 
typically from the iliac crest, and then another to implant the bone tissue at the defect site.  
Allografts and xenografts have the risk of disease transmission.  Autografts and allografts 
have problems associated with supply.  All three types have some potential for infection 
and adverse immune responses.  With the faults of the current tissue-based grafting 
techniques and the obvious need for bone graft materials, efforts have been made to use 
tissue engineering approaches to improve upon those techniques and materials.[2-8]   
 Tissue engineering is a concept whereby the biomaterial is either seeded with 
living cells before implantation (the in vitro approach) or designed to attract cells upon 
implantation (the in vivo approach).[9]  The cells, using the scaffolds as a mechanical 
support, then proliferate and differentiate and generally become metabolically active with 
the production of extracellular matrix.[8, 9]  The cells continue to become more bioactive 
and show signs of organization.  Concurrently, the degradation of the scaffold is also 
occurring with the newly regenerated tissue replacing the artificial biomaterial.[8, 9]  
With regards to bone tissue engineering, the overall goal is to use the biomaterial to 
generate a specific set of receptor-ligand responses instead of relying upon non-specific 
interactions to cause the regeneration of natural, healthy, native bone tissue.[10]   
 4
 Ideally, the tissue engineering approach would lead to a bone graft material that 
induces a regenerative response of the host bone tissue in addition to repairing the defect 
site.[9]  To do this, the bone graft material would need to be osteoconductive in that it 
would provide a conduit for the growth and expansion of the host bone tissue into the 
graft material that occupies the defect site.  It should also be osteoinductive, in that it 
would activate host osteoprogenitor cells in the surrounding tissue to induce the 
formation of new bone that would serve to fill the defect site as the graft material 
biodegrades.  The capacity to be osteogenic, meaning to have cells capable of 
proliferating and differentiating to osteoblasts, is also desirable.   
 Given the concept of tissue engineering and the limitations of natural tissue based 
bone grafts, a variety of synthetic alternatives have been developed or are being 
investigated for use as bone substitutes.  Ceramics, such as calcium sulfates, calcium 
phosphates, and hydroxyapatite, have properties similar to the mineral of bone, but are 
neither osteoinductive nor osteogenic.[1]  Another material of recent interest is the 
biopolymer, chitosan.  It has been shown to have good biocompatibility, can be shaped 
easily to match the defect site, and can induce hard-tissue mineralization.[11]  Other 
polymers and polymer blends are also being investigated.  Of these, arguably the polymer 
generating the most interest as a potential bone graft biomaterial is poly(lactic-co-
glycolic acid) (PLGA).   
 PLGA (Figure 2.1) is a biodegradable, random copolymer of varying ratios of 
poly(lactic acid) (PLA) and poly(glycolic acid) (PGA).  It has been FDA approved for 
over 30 years for a variety of applications ranging from orthopedic devices to drug 
delivery systems.[2]  It is also available commercially in a variety of molecular 
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weights.[2]  The polymerization of PLGA usually occurs by combining ring opening 
reactions of lactides and glycolides.   
 
Figure 2.1:  PLGA with lactic acid monomer (m) and glycolic acid monomer (n). 
 Many of the properties, such as crystallinity, degradation, and strength of PLGA, 
can be controlled by varying the ratio of lactic acid to glycolic acid and also by changing 
the molecular weight.[2]  Typically, PLGA does not exceed 50% glycolic acid content.  
This is primarily due to the degradation rate of PLGA being a function of the glycolic 
acid content, with higher ratios of glycolic acid leading to faster degradation rates.  
However, PGA is considered to have high crystallinity at ~ 50% [5, 12] and using more 
than 50 % PGA can lead to crystalline regions that affect the mechanical properties of 
PLGA.[8]  Another note concerning degradation of PLGA is that its products are 
naturally occurring compounds, lactic acid and glycolic acid.  Both are easily 
metabolized by the body, but can produce localized areas of high acid content if the 
vascularization is poor in that area.[8]   
With respect to crystallinity, both PLA and PGA can be crystalline and have high 
moduli.[5, 12]  As previously mentioned, PGA is highly crystalline.  In contrast, PLA is a 
chiral compound, with both the D- and L-PLA being highly crystalline, but the racemic 
mixture of the two being amorphous.  L-PLA crystallinity can reach 70%.[13]  When 
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PGA and PLA are combined to form the copolymer PLGA, much of the crystallinity, and 
therefore much of the mechanical strength is lost.  How much mechanical strength is lost 
is dependent upon the ratios of PLA to PGA and the chiral form of PLA.[14]  As a 
general rule, mechanical strength and degradation resistance are directly proportional to 
PLGA crystallinity.  Increasing the molecular weight of the PLGA chains can also result 
in increased compressive strength and modulus.[12]   
 Commercially available PLGA can be purchased with different terminal ends, 
such as carboxyl groups and hydroxyl groups.  Other research groups have made amine-
terminated PLGA as well.[15-17]  The different chemical functional groups on the ends 
of the PLGA chains allow for a variety of surface modifications to be made to PLGA.  
These surface modifications can be used to tailor the properties of the PLGA surface for 
the desired use.   
 Another advantageous property associated with PLGA is its formability.  
Numerous studies have cited a variety of fabrication methods for creating porous PLGA 
scaffolds that provide an osteoconductive template for the growth of bone tissue.[2, 4, 6, 
14, 15, 18-20]  The unifying theme in all these studies is the creation of a porous scaffold 
with pore sizes suitable for penetration of cells into the scaffold with adequate 
mechanical properties to provide a support system for cell growth while accommodating 
degradation rates creating room for cell expansion.  There have been a variety of methods 
used to fabricate these scaffolds, including solution-casting, salt-leaching, gas-foaming, 
and approaches involving the use of microspheres.[2, 4, 6, 14, 15, 18-23]  These methods 
can produce scaffolds with a wide range or porosities and mechanical properties with 
higher porosity scaffolds having lower mechanical strength than lower porosity 
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scaffolds.[2]  Each of the methods listed above, with the exception of the sintered 
microsphere approach, require the extraction of a chemical or compound to produce 
pores in the PLGA structure.  In the case of salt-leaching, salt particles can become 
trapped in the polymer scaffold resulting in poor interconnectivity of the pores.[2, 6]  
Other phase separation techniques can result in small pore diameters that limit the 
penetration of cells and tissue into the scaffolds.[2]  It has been shown, that to get good 
penetration of cells into the biomaterial, the pore diameters should be in the range of 100 
- 250 µm.[2, 24]   
 In contrast to the above mentioned methods, the sintering of PLGA microspheres 
can produce scaffolds that have pore sizes suitable for cell and tissue penetration along 
with mechanical properties similar to that of trabecular bone.[2, 7]  The "sintered 
microsphere" approach involves the fusion of adjacent, similarly sized microspheres at 
the glass transition temperature (Tg).  The result of this approach is a scaffold with near 
100% interconnectivity of the pores without the potential for other compounds to be 
trapped within the scaffold.[2, 7]   
2.2 Immobilization of Growth Factors 
 It is now known that porous, biodegradable scaffolds can be fabricated to serve as 
a temporary extracellular matrix for tissue engineering applications.  It is also known that 
high porosities with large, interconnected pores are useful for the integration of cells and 
tissue with the temporary extracellular matrix.[23, 25]  While these studies have shown 
limited success, there are additional efforts that have been made to improve 
biocompatibility and regenerative capacity of these scaffolds.  This work has largely 
involved immobilizing growth factors on the polymer scaffolds, though, there have been 
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efforts to develop growth factor delivery systems.[3, 25]  These systems could encompass 
gene, cell, or protein therapy methods.  [25-27]  
 The immobilization of growth factors can provide an improved interaction 
between the host cells and tissue and the biomaterials that are implanted, thereby 
stimulating cellular activity.  There are two general classes of immobilization techniques.  
The first being the simple adsorption of growth factors on the surface of the biomaterial.  
Certainly, growth factors and a variety of proteins will adsorb to the surface of the 
biomaterial upon implantation.[8]  However, this is truly random adsorption in that the 
interaction between the implant and the host tissue is completely uncontrolled and 
dependent upon which molecules happen to be near at the time of implantation.  A better 
approach would be to design an immobilization scheme that promotes a specific, 
controlled interaction between the implant and the host tissue.  To accomplish this, some 
have attempted to adsorb specific biomolecules on the surface by dipping the device in 
the solution containing the molecule or molecules of interest.[28, 29]  This process has 
shown some success, however since these molecules are held by weak interactions, many 
of the molecules will diffuse from the surface without eliciting the desired response.   
 The second immobilization technique is to chemically attach the biomolecules to 
the surface of the scaffold or implant before implantation.  Some are examining the 
chemical attachment of small peptides, such as Arg-Gly-Asp (RGD) containing peptides, 
to the surface of the biomaterial as a way to promote cell attachment.[3, 30-32]  The 
problem with using the RGD peptides are that many cell types have receptors capable of 
binding that peptide sequence.  This would lead to non-specific attachment of cells.  
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Therefore, there are efforts underway to examine peptides that may be more specific for 
bone cells.[30-34] 
 While the chemical attachment of peptides could lead to a specific response such 
that the implant induces regenerative bone tissue, there is still the concern of a lack of 
specificity of the peptides for the bone cells.  Chemically attaching proteins instead of 
peptides to the biomaterial surface would provide the mechanism to enhance bioactivity 
from the cells.  Whereas immobilized peptides on the surface of a biomaterial could lead 
to improved cell attachment, the immobilization of whole proteins could lead to 
improved cell attachment and to increased cellular function and differentiation.  
Furthermore, the immobilization of a particular type of protein or proteins would be more 
likely to produce specific receptor-ligand interactions that could be used to produce a 
desired outcome.  This method of attachment is essentially immobilizing growth factors 
in a manner similar to the way they would be immobilized in the extracellular matrix.   
 Another advantage of chemically attaching whole proteins or growth factors to 
the biomaterial surface is that the growth factor can be immobilized in a specific 
orientation.  Care must be taken to minimize covalent attachment of the growth factors to 
the biomaterial in locations that would otherwise be used to bind to cell receptors.  
However, if oriented immobilization can be achieved, then the growth factor can be 
oriented such that the cell-receptor binding region is in the optimal position to interact 
with cell receptors.  Positioning the growth factors on the biomaterial in that manner 
could lead to more effective integration of the biomaterial and, therefore, to an enhanced 
regeneration response for the host bone tissue. 
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 Figure 2.2 shows a cartoon comparing the random attachment of growth factors 
on the surface of a biomaterial to the oriented attachment of growth factors.  This 
demonstrates how with oriented attachment, all the cell-receptor binding regions are in 
the optimal position for interaction with the cell receptor.  In contrast, with random 
attachment of growth factors, there is no certainty that the cell-receptor binding region 
will be in a position where it can bind with cell receptors, and is obviously an inefficient 
use of the growth factors.   
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Figure 2.2:  Random versus oriented immobilization of growth factors 
2.3 Bone Morphogenetic Protein 2 (BMP-2) 
 For this research, the biomaterial of interest was PLGA and the growth factor of 
choice was BMP-2.  Part of the reason for choosing PLGA was that the ends of the 
polymer chains can have a variety of chemical functional groups that can provide ideal 
locations to immobilize growth factors.  BMP-2 was used as the growth factor because of 
its role in inducing differentiation of osteoprogenitor cells to osteoblasts.[25, 35] 
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 BMPs were first identified when implanted demineralized bone matrix (DBM) 
was observed to induce ectopic bone formation in rodents [25, 27, 36, 37] and are part of 
the transforming growth factor-β family (TGF-β).  BMP-2, a member of the BMP family, 
is a homodimer consisting of two, 114 amino acid chains that are connected by seven 
disulfide bonds, which are a prerequisite for bone induction.[35, 36, 38, 39]  The 
molecular weight of the BMP-2 monomer has been reported to be approximately 12,000 - 
14,000 Da.[38]  In addition to the differentiation of osteoprogenitor cells to osteoblasts, 
human recombinant BMP-2 (rhBMP-2) has shown osteoinductive effects on C3H10T1/2 
mouse pluripotent cells.[36]  Furthermore, experiments have shown an increase in 
osteoblastic parameters in human bone marrow such that osteoblast precursor cells were 
induced to differentiate into osteoblasts.[36, 40]  Experiments have also shown that 
BMP-2 does not stimulate mature osteoblasts or fibroblasts.[40]  This indicates that the 
osteogenic effects of BMP-2 are directed towards multipotent or pluripotent cells such as 
mesenchymal stem cells that can differentiate to chondrocytes and osteoblasts that 
develop cartilage and bone.[1, 10, 15, 25, 27, 35-37, 40-49]  BMPs have also been linked 
with accelerated fracture repair and have been shown to promote spinal fusions in in vivo 
experiments.[25, 36, 46]  
 BMP-2 interacts with cells via a complex of two types of serine/threonine-kinase 
receptor chains.  BMP receptor-IA (BRIA) and BMP receptor-IB (BRIB) are the type I 
receptors.  These are considered the high affinity receptors for BMP-2.[38, 50-54]  BMP-
receptor-II (BRII) is the second type (type II) and is considered the low affinity receptor.  
[38, 50, 52, 53, 55]  Once BMP-2 binds with the receptor, the BRII receptor 
phosphorylates the type I receptors which then phosphorylates a Smad intracellular 
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protein.  This phosphorylation sequence triggers the activation of other Smad proteins 
that eventually lead to gene transcription.[36, 49, 50, 55]  The interaction of BMP-2 with 
BRIA (Figure 2.3) involves both BMP-2 monomers and consists of a mostly hydrophobic 
contact area.[51-53]  Figure 2.3 shows a top-down view of the BMP-2:BRIA complex.  
The BMP monomers are in gold and blue with the receptors shown in green.  The chain 
termini are identified with "N's" and "C's" that represent the amino-terminus and the 
carboxyl terminus, respectively.  The "wrist" and "knuckle" epitopes refer to binding 
regions for BRIA and BRII, respectively.[51-53]  It is important to note that the receptor 
binding epitopes on BMP-2 do not include either N-terminus of the protein.  This implies 
that the N-terminus region of BMP-2 is an effective location for use in immobilizing the 
growth factor in a specific orientation to the biomaterial, PLGA.   
 
Figure 2.3:  Top-down view of BMP-2 (gold and blue portion) binding with BRIA 
receptor (green portion)[51]  (See text for detailed description) 
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2.4 Methods to Link and Orient BMP-2 to PLGA Scaffolds 
 Given the promising potential of the N-terminus of BMP-2 as a location for 
immobilizing and orienting the growth factor on the polymer, the manner in which the 
BMP-2 will be immobilized needs to be determined.  Certainly, the BMP-2 can be 
immobilized directly to the carboxyl groups of the PLGA chains.  However, there are 
reports that an optimal density of growth factors may exist for inducing a preferred 
cellular response.[32, 56, 57]  It is also known that the distance between the immobilized 
growth factor and the biomaterial surface can noticeably affect the activity of the growth 
factor.[58, 59]  In efforts to link BMP-2 to the PLGA scaffolds, chemical spacers could 
be used to control both the surface density of the BMP-2, as well as the distance from the 
PLGA substrate (Figure 2.4).  Regarding surface density of the spacer, an initial 
consideration may be to immobilize as many growth factors as possible such that they are 
packed tightly together.  However close proximity of the molecules may actually prevent 
or hinder the ability of the molecules to interact with the cell receptors simply because 
there would not be enough room between each individual BMP-2 molecule.  In a similar 
manner, the spacer could also be used to control the distance between the growth factor 
and the biomaterial surface.  If BMP-2 is too close to the surface, steric hindrance effects 
could reduce the ability of BMP-2 to bind with the receptor.  The use of a spacer that is 
too long could also lead to poor interaction between BMP-2 and the receptor due to the 
spacer lacking the rigidity to hold the growth factor in place.   
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Figure 2.4:  Illustration depicting the use of spacers to control surface density (left) 
and distance from substrate (right) of growth factors on biomaterial 
2.4.1 Dihydrazides as Spacers 
 Two different compounds were considered for use as spacers for this research.  
The first compounds chosen were dihydrazides.  Dihydrazides are symmetrical molecules 
that can have multiple methyl groups (CH2) located between two hydrazide functional 
groups (Figure 2.4.1).  The symmetry associated with dihydrazides suggests there is no 
need to use a blocking group on one end of the compound, while the other end is attached 
to the polymer surface.  Linking the dihydrazide to the biomaterial can be accomplished 
using simple carbodiimide chemistry.[60]  Another advantage of using dihydrazides as a 
spacer between the PLGA scaffolds and the BMP-2 is that the distance between polymer 
and growth factor can be easily manipulated by the addition or subtraction of methyl 
groups between the hydrazide functional groups.   
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Figure 2.4.1:  General dihydrazide structure  
2.4.2 Heparin as a Spacer Molecule 
 Heparin is a highly sulfated, extracellular matrix glycosaminoglycan (GAG) that 
has high potential as an effective spacer molecule.  Numerous studies have highlighted 
the enhancing effects of heparin on BMPs, other members of the TGF-β family, and 
growth factors in general.[15, 16, 35, 45, 48, 61-63]  One of the suggested mechanisms 
used by heparin to enhance BMP-2 bioactivity is its ability to bind the polypeptide 
noggin and prevent it from interacting with BMP-2.[15, 45, 62]  Noggin is an inhibitor of 
BMP-2 and the binding of noggin by heparin prevents its antagonistic ability on BMP-
2.[15, 45, 49, 62]  Heparin is also associated with retaining BMP-2 activity, preventing 
its degradation and increasing the half-life by 20-fold.[15, 45] 
 There is also evidence to suggest that heparin binds BMP-2 at the N-terminus 
region.[38, 48, 54]  This suggests that part of the reason for the increase in activity of 
BMP-2 is that heparin does not interfere with the cell-receptor binding regions of the 
growth factor.  It also further supports that immobilizing BMP-2 by binding the N-
terminus of the protein is an effective way of orienting the growth factor to induce 
maximum cellular activity.   
 While numerous studies have examined the effects of heparin on BMP-2, only 
one study looked at the effects of heparin-conjugated PLGA scaffolds on the activity of 
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BMP-2.[15]  The results of that study suggested that BMP-2 delivery could be sustained 
for a longer period with PLGA scaffolds that were conjugated with heparin as opposed to 
scaffolds with no heparin.  Their experiment used amine-terminated PLGA that was 
synthesized in their lab by using the ring-opening polymerization of PLA and PGA.  
They also used carbodiimide chemistry to link the carboxyl groups on heparin to the 
amine-terminated PLGA.  This is in contrast to our study which looked at immobilizing 
the heparin on the PLGA scaffolds by creating an ester bond between the hydroxyl 
groups on heparin and the carboxyl group on the PLGA chains.   
2.5 Significance 
 One could expect ever increasing incidences of trauma and bone disease as the 
U.S. population continues to age.  This will require a corresponding need for improved 
products for orthopedic care.  With regards to bone grafting techniques and materials, the 
current gold standard of treatment is the autograft, although allografts and xenografts are 
also options.  Given that no native graft and grafting procedure is without fault, there is a 
growing need for viable synthetic bone grafting biomaterials.  The immobilization of 
growth factors and other biomolecules on a bone graft biomaterial has the potential to 
improve the integration of that material with the host tissue.  If the proper types of 
biomolecules are immobilized, then the integration of the biomaterial could lead to a 
regenerative response, whereby host bone tissue is created in the defect site resulting in 
natural, healthy bone.  The bioactivity of the material could be further increased if the 
immobilization of the biomolecules occur in an oriented manner where the cell-receptor 
binding region is positioned for binding with cell-receptors.  Certainly, another advantage 
of presenting the biomolecules in an oriented manner is efficiency.  Random 
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immobilization of biomolecules on a biomaterial surface may or may not result in 
molecules that are oriented in an effective manner, increasing the likelihood of wasted 
space and molecules.   
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3 METHODS AND MATERIALS 
3.1 Polymer 
 The polymer used in this investigation was poly(lactic-co-glycolic acid) (PLGA) 
obtained from Absorbable Polymers (Pelham, AL).  It is a random copolymer with a 
50:50 ratio of lactic acid to glycolic acid and has carboxylic acid groups on the ends of 
the chains.  The molecular weight was approximately 9-23.2 kDa based on inherent 
viscosity data, and its glass transition temperature (Tg) was 42-44°C.   
3.1.1 PLGA on Coverslips 
 An 11.76% (w/v) solution of PLGA was made by adding 1.0 g of PLGA to 8.5 ml 
of dichloromethane (Sigma-Aldrich, St. Louis, MO).  The solution was vortexed until the 
polymer dissolved and then sonicated at 25 W for an additional 30 s.  The dissolved 
PLGA solution was added dropwise to coverslips (12 mm diameter, Fisher Scientific) 
until coated.  Usually 4 to 5 drops per coverslip were sufficient to coat them.  The PLGA 
coated coverslips were then allowed to air dry for approximately 15 min and then put 
under vacuum until used.   
3.1.2 PLGA coated Test Tubes 
 PLGA-coated glass test tubes (Fisher, 12 by 75 mm) were prepared in a similar 
manner to the coverslips, with the difference being that 70 µl of the 11.76% (w/v) 
polymer solution was added to each test tube.  The tubes were left under the hood to 
allow for the solvent to evaporate, leaving behind the PLGA coated test tubes.  The 
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volume of PLGA solution used was based on covering the rounded bottom portion of the 
test tube.   
3.1.3 Microspheres 
 Polyvinyl alcohol (PVA) (Sigma) was added to deionized-water (6.0 g in 600 ml).  
While the PVA was dissolving in the deionized-water, a 11.76% (w/v) solution of PLGA 
in dichloromethane was prepared by dissolving 800 mg of PLGA in 6.8 ml of 
dichloromethane then sonicating at 25 W for 90 seconds.  Once the PVA and PLGA were 
both in solution, the PLGA solution was added dropwise using a pasteur pipet to the PVA 
solution while it was being stirred using a magnetic stir bar and stir plate at 600 rpm to 
create an oil-in-water emulsion.  Care was taken to add the PLGA directly to the bottom 
of the PVA solution vortex to ensure the resulting PLGA microspheres were not too 
large.  The resulting suspension of microspheres was kept spinning at 600 rpm overnight 
to ensure that the dichloromethane solvent completely evaporated.  The PLGA 
microspheres were isolated using vacuum filtration with P4 filter paper (Fisher).  The 
microspheres were rinsed with deionized-water thoroughly and then allowed to remain 
under vacuum for another 15 min.  Finally, the microspheres were placed in a desiccator 
under vacuum until used.   
 The first modification to the previously mentioned microsphere procedure was to 
use centrifugation to recover the microspheres from suspension instead of vacuum 
filtration.  For this procedure, the PLGA/PVA emulsion was prepared exactly as 
mentioned above.  After the PLGA/PVA emulsion had spun overnight, the stirrer was 
turned off and the PLGA microspheres were allowed to settle in the beaker for 2-3 h.  
Next, the supernatant was removed, and the remaining microspheres were rinsed into a 
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50 ml centrifuge tube.  The microspheres were then centrifuged at 1500g for 10 minutes 
followed by the removal of the supernatant.  The microspheres were then resuspended in 
deionized-water and centrifuged again for 10 min.  This was repeated twice.  Following 
the three rinses, the microspheres were frozen at -70oC overnight then lyophilized for 24 
h, and stored under vacuum at room temperature with desiccant until further use.   
 A further modification in the making of the microspheres was also used.  For this 
modification, the dissolved PLGA was added to the PVA solution while using a 
homogenizer (Omni PDH) to ensure uniformity in microsphere size.  Microspheres were 
made using the homogenizer at speeds of 5500 rpm and 1500 rpm for three minutes.   
 The final modification to the microsphere preparation procedure involved the 
addition of the dissolved PLGA solution to the PVA solution using a pasteur pipet as 
mentioned above.  This time, the magnetic stirrer was set to 450 rpm and the dissolved 
PLGA was added rapidly (instead of dropwise) to the outer edge of the vortex (instead of 
to the bottom of the vortex) and allowed to stir overnight.  The resulting microspheres 
were isolated by using vacuum filtration, then frozen overnight at -70°C before 
lyophilizing for 24 h.  Microspheres were then stored under vacuum at room temperature 
with desiccant until use.   
3.1.4 PLGA Scaffolds 
 PLGA scaffolds were prepared based on the sintered microsphere approach.[2, 6, 
7]  Scaffold preparation began by using a mortar and pestle to gently break up the 
clumped microspheres.  The microspheres were then sieved to isolate the microspheres 
with diameters of 50 - 150 microns.  Microspheres with diameters greater than 150 
microns were also kept.  Initially all scaffolds were made by pouring 25 mg of the 50-150 
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micron microspheres into a mold having cylindrical holes that were 5 mm wide and 6 
mm deep and then heating at Tg (~ 43°C) for 24 h.  Heating at this temperature served to 
fuse the microspheres together without completely melting them into one solid mass.  
The fused microspheres created an interconnected porous scaffold.   
 A modification of this procedure for making scaffolds was to pour the loose 
microspheres into the mold, taking care to completely fill all the mold holes with 
microspheres, then giving the mold a gentle tap to settle the microspheres before placing 
in the oven at Tg for 24 h.  This version of the procedure was much less tedious to 
perform, and it resulted in larger scaffolds with less variability in the shape of the 
cylinder.  After 24 h, the scaffolds were allowed to cool to room temperature before 
being removed from the mold.  The scaffolds were stored in a freezer in a desiccator until 
used.   
3.2 Material Characterization 
3.2.1 Particle Size Testing 
 Particle size testing was accomplished using a Horiba Partica LA-950 laser 
scattering particle size distribution analyzer.  Briefly, the procedure involved suspending 
approximately 0.5 g of the PLGA microspheres in deionized water then pipetting the 
suspension into the inlet on the machine.  This was done to determine the range and 
distribution of the microspheres prepared by the various methods mentioned above before 
the microspheres were sieved for use in scaffold construction.   
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3.2.2 Porosity 
 The PLGA scaffolds made by sintering 25 mg of 50-150 micron diameter 
microspheres together were characterized by mercury intrusion porisometry (MIP) using 
a Micromeritics AutoPore IV 9500.  Percent porosity and pore size distribution were 
provided in the output from the equipment.  To determine the surface area of the 
scaffolds, the mass of the sample used was multiplied by the total pore area (m2/g) to give 
total area.  This area was divided by the total number of scaffolds used to get surface area 
per scaffold.   
3.2.3 Scanning Electron Microscopy (SEM) 
 Initial scaffolds (25 mg) were mounted on an SEM stub using colloidal graphite 
(Ted Pella, Inc. Redding, CA).  Each stub underwent gold sputter coating in an argon 
atmosphere using the Emscope sc 400.  The samples were then viewed using a Hitachi S-
3200 (Tokyo, Japan) with an accelerating voltage of 5kV.  Scaffolds that were made by 
filling the entire mold with PLGA microspheres were prepared in a similar manner to the 
previously mentioned scaffolds, but were viewed using a Hitachi S-2700 SEM-EDX 
(Tokyo, Japan).  In both cases, SEM pictures were taken of the surface and of cross-
sections of the scaffolds.     
3.2.4 Mechanical Testing of Scaffolds 
 Compressive strength and modulus were determined for the scaffolds made by 
pouring microspheres into the mold using a Bose Electroforce 3300 Mechanical Testing 
System with WinTest 3.0 software.  Testing was conducted under displacement control 
using a 50 lb (222.5 N) load cell.  Once the system was calibrated/tared and the crosshead 
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was in the correct position, the samples were loaded to failure utilizing compression 
platens.  Testing was done at a rate of 1 mm/minute.  The data was converted to 
Microsoft Excel format then and the force-displacement data was converted to stress-
strain curves.  Strain was determined from the values for displacement and the original 
height of the scaffolds.  The slope of the initial linear portion of the stress-strain curve 
was then used to determine the modulus.  The compressive strength was estimated by 
determining the stress just after the initial linear portion of the stress-strain curve.   
3.3 Surface Modification 
 All surface modification attempts were based on using the free carboxyl group at 
the end of the polymer chains to attach either dihydrazides of multiple carbon chain 
lengths or to attach heparin.  The chemistry used to attach the spacers and the 
quantification methods are discussed in the following sections.   
3.3.1 Hydrazides 
 The hydrazide groups on either end of the dihydrazides make the compounds 
ideal for linking proteins and other bone growth factors to the PLGA backbone.  Four 
different dihydrazides were used.  They were oxalic dihydrazide (Alfa Aesar), succinic 
dihydrazide (Aldrich), adipic dihydrazide (Sigma), and sebacic dihydrazide (TCI 
America).  See Figure 3.3.1a for the structures.   
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Figure 3.3.1a:  Dihydrazide structures 
 To get the dihydrazides to react with the carboxyl groups of the PLGA, they were 
first dissolved in 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) (Sigma), pH 6.0.  
To activate the surface of the PLGA backbone for attachment of the dihydrazides, a 0.067 
mM solution of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDAC) 
(Sigma) and 0.027 mM N-hydroxysuccinimide (NHS) (Fluka) was used (see Figure 
3.3.1b).  Each PLGA sample had 0.5 ml of the appropriate dihydrazide solution and 0.5 
ml of the EDAC/NHS solution added to them, regardless of whether it was a PLGA 
coated coverslip, coated test-tube, or scaffold.  These were allowed to react for two hours 
at room temperature with gentle shaking, and then the samples were rinsed three times 
with deionized water to remove the excess reactants.  The next step was to either quantify 
the dihydrazides or to add the bone growth factors.   
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Figure 3.3.1b:  Reaction scheme for the addition of dihydrazides to carboxyl groups 
on the ends of the PLGA chain 
3.3.1.1 Quantification of Dihydrazides with TNBS 
 Quantification of the dihydrazides on the PLGA was accomplished using a couple 
of methods.  The first method used a solution of 0.1% (w/v) 2,4,6,-trinitrobenzene 
sulfonic acid (TNBS) (Sigma) in 3% sodium borate (Sigma).  The TNBS solution (0.5 
ml) was added to the rinsed PLGA-dihydrazide samples and heated at 70°C for 5 min, 
causing a reaction where the free hydrazide group displaces the sulfonate group to form a 
covalent bond with the remaining trinitrophenyl group.  Next, 0.5 ml of 1 M NaOH was 
added to the samples and heated for an additional 10 min to hydrolyze the trinitrophenyl 
group.  This hydrolysis step produced a yellowish-orange color that could be measured at 
450 nm with a plate reader (Dynatech MR5000).  The absorbance values of the samples 
were then compared to those values produced from a standard curve produced with 
known concentrations of dihydrazides to quantify the dihydrazides.   
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3.3.1.2 Quantification of dihydrazides with Alexa 350 
 Another method of quantification used was to react the hydrazides with the 
fluorophore Alexa 350 (Invitrogen).  This method was only used for the PLGA coated 
test tubes and PLGA scaffolds.  First, 5 mg of Alexa was dissolved in dimethyl sulfoxide 
(DMSO) (Sigma), giving a 8.123 mM stock Alexa solution.  After aspirating the excess 
dihydrazides and rinsing the dihydrazide-treated PLGA samples with deionized water, 7 
µl of Alexa 350 stock solution and 1.0 ml of PBS, pH 7.4, were added to each sample.  
The samples were then covered to keep light out and allowed to react for one hour.  The 
excess Alexa was aspirated, and the remaining PLGA-dihydrazide-Alexa 350 component 
was dissolved in 1.0 ml of 100% acetone (Fisher).  Fluorescence (excitation 346 nm, 
emission 443 nm) of the samples was then measured using a fluorometric plate reader 
(SpectraMax Gemini XS) with 0.1 ml of the dissolved Alexa- and dihydrazide-treated 
PLGA samples per well.  These values were then compared to a standard curve 
constructed from the Alexa stock solution.   
3.3.2 Heparin 
 A variety of methods were attempted to attach heparin (Sigma, ~13K MW) to the 
PLGA scaffolds directly and through the dihydrazide spacers.  For detection of heparin, 
two methods of quantification were accomplished.  These will be discussed in the 
sections that follow.   
3.3.2.1 Oxidation of Heparin with Sodium Periodate 
 Sodium periodate (Sigma) was used to oxidize diols on the heparin chain to 
aldehydes.  Briefly, 250 µl of 10 mM sodium periodate was added to 250 µl of a 40 
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µg/ml heparin stock solution.  The sample was allowed to react in the dark for 45 minutes 
and then was quenched using 0.5 ml of a 10% glycerol solution.  The sample was then 
filter centrifuged (Micron, Ultracel YM-3, 3000 MWCO) at 10,000g for 90 minutes to 
separate the oxidized heparin from the excess glycerol.  Next, the filtered samples were 
rinsed with PBS, pH 7.4.  The resulting oxidized heparin solution was diluted to 10 ml 
with deionized water and compared to a standard curve produced using the commercially 
available Blyscan assay (Biocolor, United Kingdom) to determine the yield of oxidized 
heparin.   
 
Figure 3.3.2.1:  Reaction scheme for the oxidation of heparin diols to aldehydes 
The procedure for using the Blyscan assay was as directed by the manual.  
Briefly, 100 µl of the sample was added to 1.0 ml of dye reagent and allowed to mix for 
30 minutes.  Next, the sample and dye reagent solution were centrifuged at 10,000g for 
10 minutes, followed by removal of the supernatant liquid.  Care was taken not to 
dislodge the bluish purple pellet.  The Blyscan dissociation reagent (1.0 ml) was then 
added and vortexed to bring the pellet back into solution.  The absorbance was measured 
at 656 nm and compared to a standard curve constructed using known quantities of 
heparin.   
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3.3.2.2 Heparin Addition with 1,1’-Carbonyldiimidazole 
 The method used to attach heparin directly to the PLGA scaffolds utilized 1,1’-
carbonyldiimidazole (CDI) (Sigma) (Figure 3.3.2.2).[64]  For this procedure, the 
scaffolds were soaked in 200-proof ethanol (Sigma) for 15 min using 0.5 to 1.0 ml of 
ethanol per scaffold.  The ethanol was aspirated from the scaffolds followed by the 
addition of deionized water.  Just enough deionized water was added to prevent the 
scaffolds from being completely submerged.  Care was taken to note the volume added, 
then enough CDI was added slowly over a 15 min period to make a 0.2 M solution.  The 
CDI solution was then aspirated from the scaffolds.   
 
Figure 3.3.2.2:  Reaction scheme for the addition of heparin to the carboxyl group 
on the ends of the PLGA chain 
 To compare heparin addition as a function of CDI treatment, excess heparin (0.5 
ml of 1 mg/ml) was added to scaffolds treated with CDI and to scaffolds without CDI 
treatment, then both were diluted to 1.0 ml with 0.2% (w/v) NaCl solution.  Blanks had 
only 1.0 ml of 0.2% (w/v) NaCl added to them.  All scaffolds were then allowed to react 
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overnight on a rotator.  The rotator was used to increase penetration of the heparin into 
the pores of the scaffold.  After reacting overnight, the excess heparin was aspirated and 
the scaffolds were rinsed twice with deionized water.   
3.3.2.3 Heparin Quantification  
 Heparin quantification on scaffolds involved the use of toluidine blue (t-blue) 
(Fisher Biotech) and the procedure referenced by Hermanson et al.[65]  Here, 0.6 ml of 
0.005% t-blue in 0.01 N hydrochloric acid containing 0.2% (w/v) NaCl and 0.4 ml of a 
separate 0.2% (w/v) NaCl solution were added to each scaffold after they were rinsed of 
excess heparin and allowed to react for 2 h on the rotator.  After reacting for 2 h, the 
absorbance of the supernatant was measured at 631 nm using a Hitachi U-2000 
spectrophotometer.  These absorbance values were compared to a standard curve made 
with known heparin concentrations ranging from 6 µg/ml to 21 µg/ml.  The Blyscan 
assay had a limited range and effectiveness with heparin attached to PLGA and was not 
used to quantify heparin attached to PLGA scaffolds.   
3.3.3 Bone Morphogenetic Protein-2 Attachment  
 Human recombinant BMP-2 (1.0 mg) was obtained from Kamiya Biomedical 
Company in lyophilized form combined with an equal amount of human serum albumin 
(HSA).  This was suspended in 0.5 ml of PBS, pH 7.4, and 0.5 ml of ultra-pure water 
then filtered using a SwellGel Blue Albumin Removal Kit (Pierce) per the manufacturer’s 
instructions to remove the albumin.  To determine the amount of BMP-2 available after 
using the albumin removal kit, a BCA assay (Pierce) was used as directed by the 
manufacturer's instructions.   
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 Each heparin-loaded scaffold had 10 µg of BMP-2 added to it.  This was slightly 
less than twice the mass of heparin that was attached to the scaffolds and yields a molar 
ratio of approximately 1:1 BMP-2 to immobilized heparin.  PBS was added to make the 
final volume of BMP-2 solution 1.0 ml per scaffold.  The scaffolds were allowed to react 
while on the rotator for 24 h.  The excess BMP-2 solution was aspirated, and the 
scaffolds were rinsed twice with deionized water before the BMP-2 detection steps 
began.   
3.3.3.1 Bone Morphogenetic Protein-2 Quantification 
 Detection of BMP-2 on the scaffolds was completed using a microBCA assay 
(Pierce).  The instructions from the manufacturer were followed for construction of the 
standard curve and the mixing of the working reagent solution.  Adaptation of the 
protocol for the detection of protein on the scaffolds involved the addition of 0.5 ml of 
the working reagent to each sample and incubation at 37°C with gentle shaking for two 
hours.  After two hours, the absorbance of the samples was measured using a microplate 
reader (Dynatech MR5000) at 570 nm.  These absorbance values were compared to a 
standard curve constructed using a stock bovine serum albumin (BSA) standard.   
3.3.3.2 Bone Morphogenetic Protein-2 Orientation   
 Orientation of BMP-2 was probed using antibodies for the N- or C-terminus of 
BMP-2 (Santa Cruz Biotech; SC-6985 for N-terminal and SC-6267 for C-terminal 
antibodies).  The procedure for attaching BMP-2 to the scaffolds was identical to the 
procedure mentioned in section 3.3.3.  Scaffolds were blocked using 0.5 ml of 0.5% 
(w/v) BSA (Sigma-Aldrich) in 0.05% Tween 20 (Sigma) in PBS (PBST) after being 
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rinsed of excess BMP-2.  This was allowed to react for 30 minutes on the rotator.  Excess 
BSA was rinsed off twice in 0.5 ml of PBST.  The primary antibody, goat IgG against N- 
or C-terminus of human BMP, was diluted 1:200 with PBS (90 µl in 18 ml of PBS) and 
added at 0.5 ml per sample.  Samples were allowed to react for 30 minutes at 37°C with 
gentle shaking.  The excess primary antibody was aspirated off, and the samples were 
rinsed twice with PBST.  The secondary antibody, anti-goat antibody conjugated to 
alkaline phosphatase, developed in rabbit (Sigma), was diluted 1:8000 (3 µl in 24 ml) and 
then added at 0.5 ml per scaffold.  The samples were allowed to react for 45 minutes at 
37°C with gentle shaking.  Again, the excess was removed, and the samples were rinsed 
twice with PBST.  Finally, 0.5 ml of 0.1% (w/v) Sigma 104 phosphatase substrate 
(Sigma) in 10% (v/v) diethanolamine (Curtin Matheson Scientific Inc, Houston, TX) was 
added to each sample and allowed to react for 1 hour at 37°C.  The absorbance of 100 µl 
of each sample was then measured at 410 nm.  The absorbance values were then used to 
determine the effectiveness of the orientation procedure.  This was done by comparing 
the ratio of the absorbance values obtained to the mass of BMP-2 that was on the 
scaffolds.   
3.4 C3H10T1/2 Cells and Scaffold Bioactivity 
 C3H10T1/2 mouse pluripotent cells (CCL-226; ATCC, Rockville MD) were used 
to assess the bioactivity of the BMP-2 loaded scaffolds.  The first step in the process was 
to load heparin and BMP-2 as directed above, but in a sterile environment.  Four groups 
of scaffolds were created to compare oriented BMP-2 attachment to random adsorption of 
BMP-2 on the scaffolds (Table 3.4).  Scaffolds that had adsorbed heparin (no CDI) with 
BMP-2 loaded on them made up the first group.  The second group was comprised of 
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scaffolds with BMP-2 that were without heparin and without CDI activation.   The third 
group of scaffolds had covalently linked heparin with BMP-2.  Scaffolds that were made 
without heparin present, but were activated with CDI before the addition of BMP-2 
comprised the fourth group.  A fifth set of scaffolds that had no heparin and no BMP-2 
treatment was also created.  Once these five categories of scaffolds were prepared, they 
were placed in individual wells of a 96 well plate and 250 µl of αMEM containing 1% 
fetal bovine serum (FBS) medium (Invitrogen) containing 100,000 cells were added to 
each well.  In addition, a group of scaffolds without heparin or BMP-2 immobilized on 
them were also placed in wells.  These acellular scaffolds were placed in 250 µl of 1% 
FBS medium.  The scaffolds were then incubated at 37°C for three days.  Following 
incubation, the scaffolds were removed from the wells and placed in individual 2.0 ml 
centrifuge tubes.  They were then rinsed twice with PBS followed by the addition of 1.0 
ml of high salt buffer (0.05 M NaH2PO4, 2 M NaCl, 2 mM EDTA, pH 7.4).  The 
scaffolds were then frozen at -70°C overnight and thawed the following morning.  The 
freeze-thaw cycle was repeated twice to ensure that the cells were lysed.  Following the 
final freeze-thaw cycle, the scaffolds were sonicated at 25 W to break up the scaffolds 
and any remaining whole cells.  Samples were then centrifuged at 4500g for 2 minutes to 
separate the scaffold material from the cell material.   
Table 3.4:  Scaffold Treatment by Category for Bioactivity Determination  
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
Hep+BMP BMP Hep+BMP BMP No Hep No Hep
No BMP No BMP
No Cells
No CDI CDI
C3H10T1/2 Cells  
 A Hoechst DNA assay was then run on the samples to determine DNA content.  
Briefly, 50 µl of a 0.5 µg/ml Hoechst 33258 solution was added to 200 µl of the 
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supernatant from above.  The mixture was given a gentle shake before letting stand, 
covered from light, for 10 minutes.  The fluorescence was then measured (356 nm 
excitation, 458 nm emission), and the values were recorded and compared to a standard 
curve constructed with known amounts of calf thymus DNA. 
 An alkaline phosphatase (AP) assay was also completed to determine the activity 
of the BMP-2 for each set of scaffolds.  First, a substrate solution that was 10 mM Sigma 
104 phosphatase substrate (Sigma), 0.6 M 2-amino-2-methyl-1-propanol buffer, and 4 
mM MgCl2 was prepared.  This was then cooled to near freezing.  Next, 50 µl of the 
substrate solution was added to 10 µl of the cell lysate and incubated at 37°C for 30 
minutes.  Absorbance was then measured at 410 nm.  Activity was expressed as nmoles 
of substrate cleaved per minute (nmol/min) and normalized by total intracellular protein 
(nmol/min/µg DNA).   
3.5 Statistical Analysis 
 Unless otherwise stated, the sample size was six for all experiments.  All the 
graphs in the results section are displayed as the mean ± the standard deviation.  
Statistical analysis was performed using INSTAT3 software (Graphpad software, inc.).  
One way ANOVA was the primary method used to compare means from multiple groups 
for statistical significance.  When appropriate, the Tukey Kramer multiple comparison 
test was used to compare the different experimental groups.   
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4 RESULTS 
4.1 Microsphere Characterization using Particle Size Testing 
Particle size testing was accomplished on the microspheres produced with the use 
of the homogenizer as described in section 3.1.3 and on spheres that were produced when 
the magnetic stirrer was set to 450 rpm, also described in section 3.1.3.  The results from 
testing the microspheres made using the homogenizer yielded a mean diameter of 
approximately 40 microns, which was too small for our use.  The distribution of particle 
sizes for the spheres made with a magnetic stirrer at 450 rpm is shown in Figure 4.1.1.  
The median and mean particle diameters for those were 146 microns and 180 microns, 
respectively.   
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Figure 4.1.1:  Particle size distribution for microspheres 
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4.2 Scaffold Characterization 
4.2.1 General Scaffold Characterization 
 Pictures of the scaffolds are shown in the next two figures.  The first picture 
(Figure 4.2.1a) shows a batch of scaffolds that were prepared by pouring microspheres 
greater than 150 µm in diameter into the mold and then heating at the Tg for 24 hours.  
The dimensions (approximately 4.8 mm diameter by 5.8 mm high) of the scaffolds can be 
seen in the second picture (Figure 4.2.1b).  The scaffolds have a mass of approximately 
55 mg and a density of 0.58 g/ml.   
 
Figure 4.2.1a:  Picture of PLGA scaffolds showing similar size and shape 
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Figure 4.2.1b:  Picture showing scaffold dimensions 
4.2.2 Mercury Intrusion Porosimetry  
Results from mercury intrusion porosimetry (MIP) testing of the initial 25 mg 
scaffolds made with 50-150 µm microspheres are shown in Table 4.2.2.   The average 
porosity was 47.0% with a total pore area of 0.073 m2/g per 15 scaffolds, resulting in an 
average surface area of 1633 mm2 per scaffold.   
Table 4.2.2:  Mercury Intrusion Porisometry Data 
units Group 1 Group 2 Group 3 Average std dev
mL/g 0.7729 0.7682 0.7215 0.7542 0.0284
m2/g 0.079 0.073 0.068 0.073 0.0055
µm 38.3991 41.3219 41.8667 40.5292 1.8648
µm 29.0107 31.0564 32.8055 30.9575 1.8993
µm 39.3351 42.0678 42.5957 41.3329 1.7501
g/mL 0.6144 0.6100 0.6466 0.6237 0.0200
g/mL 1.1701 1.1481 1.2122 1.1768 0.0326
porosity % 47.4896 46.8647 46.6545 47.0029 0.4344
median pore diameter(area)
average pore diameter(4V/A)
bulk density at 0.21psia
apparent (skeletal density)
Porosimeter data
total intrusion volume
total pore area
median pore diameter(vol)
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4.2.3 Scanning Electron Microscopy 
Scanning electron microscopy of scaffolds made with 50-150 µm microspheres 
revealed a structure that visually appeared more solid than porous when compared to 
scaffolds made with microspheres greater than 150 µm.  An SEM image (Figure 4.2.3a) 
of the cross-section of a scaffold made with spheres < 150 µm in diameter shows that 
there were a few pores present with sizes greater than 100 µm.  It was also observed that 
most of the microsphere sizes were smaller than the 50 µm minimum that was desired.  
Another SEM picture (Figure 4.2.3b) shows the surface of the scaffold made with the 
smaller diameter (<150 µm) microspheres.  Again, there are pores present, but overall the 
scaffold appears more solid than it does porous.   
 
Figure 4.2.3a:  Cross section of scaffold made with <150 µm diameter microspheres 
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Figure 4.2.3b:  Surface of scaffold made with <150 µm diameter microspheres 
Scaffolds made with greater than 150 µm diameter microspheres showed much 
better porosity with some pore sizes over 200 µm in diameter based on SEM pictures.  
Figure 4.2.3c shows the cross-section of a scaffold made with the larger diameter 
microspheres and at a similar magnification as the cross-section of the scaffold made 
with smaller microspheres shown in Figure 4.2.3a.  An SEM picture showing the surface 
view of a scaffold made with larger microspheres is shown in Figure 4.2.3d.   
Another observation from the SEM pictures was that not all of the microspheres 
were greater than 150 µm as intended.  Rather, there were aggregates of small diameter 
microspheres that had diameters greater than 150 µm.  Nonetheless, there was still good 
porosity and good pore size with the larger diameter microspheres, especially when 
compared to the scaffolds made with smaller microspheres.   
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Figure 4.2.3c:  Cross-section of scaffold made with >150 µm diameter microspheres 
 
Figure 4.2.3d:  Surface of scaffold made with >150 µm diameter microspheres 
4.2.4 Mechanical testing 
 Results for compressive strength and modulus of the scaffolds tested are shown in 
Table 4.2.4.  These results were for scaffolds made with >150 µm diameter microspheres 
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and show an average compressive strength of 2.36 ± 0.23 MPa and an average modulus 
of 30.1 ± 4.4 MPa.  The production of scaffolds made with spheres <150 µm in diameter 
had already been discontinued when the Bose mechanical tester had become available, 
therefore there are no mechanical testing results for those scaffolds.   
Table 4.2.4:  Compressive Strength and Modulus of PLGA Scaffolds. 
Scaffold Strength Modulus
(MPa) (MPa)
1 2.17 38.9
2 2.43 28
3 2.26 29.5
4 2.54 27.1
5 2.07 27.9
6 2.66 29.4
avg = 2.355 30.13333
std dev = 0.22687 4.393935  
4.3 Surface Modification 
4.3.1 Dihydrazides 
The four different dihydrazides used (see Figure 3.3.1 from Section 3) were 
attached to PLGA using EDAC/NHS chemistry and were initially quantified using a 
TNBS assay and later, using an Alexa fluorophore assay.  The TNBS assay was used to 
detect adipic dihydrazide (AAD) that was attached to PLGA-coated test tubes.  Multiple 
initial concentrations (0.018, 0.057, 0.115, and 0.184 mM) of AAD were used to 
determine if it was possible to vary the amount of AAD on the surface by controlling the 
initial concentration.  The results (Figure 4.3.1a) in increasing numbers of molecules 
from lowest concentration to highest concentration, were 1.73 ± 2.3 x 1015 molecules for 
the lowest concentration to 3.4 ± 7.97 x 1015 molecules for the next, then to 4.59 ± 2.65 x 
1015 molecules for the third highest concentration, and finally to 5.22 ± 4.0 x 1015 
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molecules at the highest concentration of 0.184 mM AAD.  The estimated surface area of 
polymer on the test tubes was 3.67 x 108 µm2.  Using that estimated area, the density of 
AAD molecules on the PLGA surface was determined and is also shown in Figure 4.3.1a.  
The surface densities ranged from 4.72 ± 6.24 x 106 molecules per µm2 for the lowest 
initial concentration to 1.42 ± 1.1 x 107 molecules per µm2 at the highest initial 
concentration.  The trend on each of the graphs was as expected with higher initial 
concentrations having more molecules and a higher surface density than did the lower 
initial concentrations.  The increase in the total number of molecules as the concentration 
increased was not linear however.  For example, for a nearly three-fold increase in initial 
concentration of AAD from 0.018 to 0.057 mM there was a less than two-fold increase in 
the total number of AAD molecules retained and in the surface density for the same 
increase in concentration.  Similarly, a nearly 10-fold increase from the lowest to the 
highest initial AAD concentration resulted in only a 3-fold increase in the AAD 
molecules retained and surface density.  Statistical analysis using ANOVA indicated no 
significant difference between the mean values for each group.   
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Figure 4.3.1a:  Number and surface density of AAD molecules attached to PLGA-
coated test tubes as a function of initial starting concentration 
 The first efforts to quantify dihydrazides using Alexa 350 were made using 
PLGA-coated test tubes to compare retention of dihydrazides on the PLGA when starting 
with equal molar amounts of each.  The initial concentration was 131 mM for each 
dihydrazide and 0.5 ml (0.0656 mmol) were added to each PLGA-coated test tube.  The 
results indicated that, given equal starting amounts in moles of the hydrazides, longer 
chain lengths led to more hydrazides being attached to the surface (See Figure 4.3.1b).  
ANOVA indicated that the molecules retained for the C10 dihydrazide group were 
significantly greater than the other groups (p < 0.001 for all three comparisons).  There 
was no statistical difference between the C2, C4, and C6 dihydrazide groups.   
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Figure 4.3.1b:  Dihydrazides attached to PLGA-coated test tubes as a function of 
dihydrazide length 
 Another experiment was done using AAD and PLGA-coated test tubes, this time 
using Alexa 350 to determine the effect of different starting concentrations of the same 
dihydrazide on retention.  This was similar to the experiment above that used TNBS to 
quantify the AAD.  The results showed four times the number of AAD molecules 
remaining for a 10 and 100 fold increase in the initial amount of molecules (Figure 
4.3.1c).  The only significant difference, as determined by statistical analysis using 
ANOVA, was between the high and low starting concentrations (p < 0.05).   
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Figure 4.3.1c:  AAD molecules attached to PLGA-coated test tubes as a function of 
initial starting concentration  
4.3.2 Dihydrazides and Heparin 
 Early on, efforts were made to link oxidized heparin to the dihydrazides that were 
previously attached to the polymer surface.  To determine the amount of oxidized heparin 
available after going through the oxidation process, the Blyscan assay was used.  The 
results were an approximately 80% yield of oxidized heparin as compared to the initial 
mass.   
 However, the Blyscan assay was not effective at quantifying oxidized heparin that 
was attached to the dihydrazides on the PLGA coated test tubes.  Efforts were made to 
attach oxidized heparin in a 1:1 molar ratio with the dihydrazides.  Quantification of 
heparin immobilized in this manner was done using the Blyscan assay.  However, the 
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results yielded no separation of absorbance values for samples that had oxidized heparin 
added to them compared with the absorbance values for blanks that were only PLGA.  
Further experiments determined that PLGA masked the Blyscan signal, preventing 
accurate detection of heparin attached to the polymer.   
4.3.3 Heparin Alone 
 After the difficulties attaching oxidized heparin to the PLGA coated test tubes via 
the dihydrazides, it was decided to bypass using the dihydrazides and to link heparin 
directly with the polymer.  To do this, 1,1’-carbonyldiimidazole (CDI) was used to create 
an ester linkage between the heparin hydroxyl groups and the free carboxyl groups on the 
ends of the PLGA chains.  Experiments were designed to compare covalent heparin 
attachment using CDI with randomly adsorbed heparin on the surface of the PLGA 
scaffold.   
Multiple sets of data need to be compared with regards to heparin attachment 
beyond the comparison of covalent attachment with CDI and random adsorption without 
CDI.  When this experiment was initially conducted, the PLGA molecular weight was 
approximately 17 kDa (based on the viscosity data supplied with the PLGA source) and 
less than 150 µm diameter microspheres were used to make the scaffolds.  Subsequently, 
it was decided to make the scaffolds using microspheres that were greater than 150 µm in 
diameter.  Another variable was introduced when the original PLGA supply was 
exhausted.  The new PLGA had a molecular weight (9.3 kDa) nearly half that of the 
original polymer used.  Therefore, scaffolds made with 17 kDa PLGA and microsphere 
sizes greater than 150 µm were compared to scaffolds from the same molecular weight 
PLGA made with less than 150 µm spheres (Figure 4.3.3a).  In this scenario, scaffolds 
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made with large microspheres that used CDI to covalently attach heparin had 16.03 ± 
8.48 µg of heparin attached compared to only 3.45 ± 2.01 µg of adsorbed heparin on 
scaffolds made with the same larger microspheres (p < 0.01).  In contrast, scaffolds made 
with 17 kDa PLGA and less than 150 µm microspheres had 8.06 ± 2.02 µg for covalently 
attached PLGA and 2.6 ± 2.3 µg for adsorbed heparin.  This difference was not 
statistically different.   
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Figure 4.3.3a:  Amount of heparin on scaffolds made with 17 kDa PLGA as a 
function of heparin attachment type and microsphere size 
 Heparin loading experiments were also conducted on scaffolds made with the 
lower MW PLGA that was obtained after all the 17 kDa PLGA had been consumed.  All 
of these scaffolds were made with microspheres greater than 150 µm in diameter.  The 
mass of heparin attached to scaffolds made with this MW PLGA was 6.64 ± 3.53 µg for 
covalently attached heparin using CDI and 4.73 ± 1.77 µg for adsorbed heparin (Figure 
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4.3.3b)  However, a t-test performed on the two groups indicated that the difference was 
not statistically significant.   
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Figure 4.3.3b:  Amount of heparin on scaffolds made with 9.3 kDa PLGA as a 
function of heparin attachment type  
4.4 BMP-2 Attachment 
 Results from BMP-2 attachment are shown in Figure 4.4.  Scaffolds with heparin 
covalently attached had more BMP-2 linked (1.23 ± 0.53 µg) than either scaffolds that 
had CDI treatment without heparin addition (0.767 ± 0.30 µg) or scaffolds that had BMP-
2 linked to adsorbed (no CDI treatment) heparin (0.468 ± 0.14 µg).  The mass of BMP-2 
adsorbed to the surface of the scaffolds was 0.443 ± 0.15 µg.  Statistical analysis using 
ANOVA revealed that differences between BMP-2 immobilized with the covalently 
linked heparin was significantly different than either the BMP-2 loaded on scaffolds with 
adsorbed heparin (p < 0.01) or the BMP-2 that adsorbed to the scaffold surface without 
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heparin (p < 0.01).  The difference was not significant when compared to BMP-2 that 
was immobilized on scaffolds that had CDI treatment, but did not have attached heparin.   
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Figure 4.4:  Amount of BMP-2 immobilized on PLGA scaffolds as a function of 
heparin loading type and/or CDI treatment 
4.5 BMP-2 Orientation 
 The absorbance values for the N- and C- terminus antibody tests are shown in 
Figures 4.5a and 4.5b.  The ratios of the absorbance values for the N- and C- terminus 
antibody test to the mass of BMP-2 on the different scaffold categories are shown in 
Table 4.4.  The absorbance values and their ratios to the mass of BMP-2 immobilized 
were used to determine the effectiveness of immobilized heparin at orienting BMP-2 on 
the PLGA scaffolds.  These results were not conclusive with regards to determining 
whether the BMP-2 was immobilized in the desired orientation.  None of the differences 
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were statistically significant.  However, the results did confirm the presence of BMP-2 on 
the scaffolds.   
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Figure 4.5a:  N-terminal antibody test on BMP-2 loaded scaffolds 
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Figure 4.5b: C-terminal antibody test on BMP-2 loaded scaffolds 
Table 4.5:  Ratios of Absorbance to BMP-2 Mass on PLGA Scaffolds 
Hep+BMP BMP Hep+BMP BMP
N-terminus 0.000 0.002 0.011 0.003
C-terminus 0.091 0.036 0.017 0.053
No CDI CDI
 
4.6 C3H10T1/2 Cells and Scaffold Bioactivity 
 The DNA and AP assay results are listed in Table 4.6 and shown in Figure 4.6a 
and 4.6b.  Results of the DNA assay indicated that there was almost twice as much 
cellular growth on the scaffolds that did not use CDI (groups 1 & 2) to activate the PLGA 
carboxyl groups compared to the scaffolds that did use CDI (groups 3 & 4).  The 
scaffolds without BMP-2 immobilization (group 5) also had more cell growth than did 
the CDI activated scaffolds with BMP-2 immobilization.   
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Table 4.6:  Responses of C3H10T1/2 Cells to Scaffolds with Immobilized BMP-2 
Group 1 Group 2 Group 3 Group 4 Group 5
Hep+BMP BMP Hep+BMP BMP No Hep
No BMP
DNA (µg) 0.156±0.040 0.147±0.027 0.076±0.032 0.060±0.022 0.113±0.029
AP Activity 
(nmol/min/µg DNA) 7.51±2.08 5.99±0.34 18.95±2.56 18.39±7.47 9.62±2.58
AP Activity 
Normalized    
(per µg BMP-2) 16.05 13.52 15.41 23.98
C3H10T1/2 Cells
No CDI CDI
 
The AP activity assay results indicated that the oriented immobilization of BMP-2 
using covalently attached heparin (group 3) stimulated significantly greater activity than 
both scaffolds that had BMP-2 simply adsorbed without heparin or CDI activation (group 
2) (p<0.001) and scaffolds that used adsorbed heparin to immobilize BMP-2 (group 1) 
(p<0.001).  The results also indicated no significant difference in activity between 
scaffolds that had been activated with CDI, regardless of the presence of heparin (groups 
3 & 4).  However, there was nearly 50% error associated with scaffolds that had BMP-2 
randomly immobilized directly to scaffolds with CDI activation and no heparin present 
(group 4) compared to only approximately 13% error with scaffolds that used covalently 
attached heparin to immobilize the BMP-2 (group 3).  Scaffolds without either BMP-2 or 
heparin (group 5) present had greater activity than did both sets of scaffolds from groups 
1 and 2, although this difference was not statistically significant.  The difference in 
activity between those scaffolds without BMP-2 or heparin present and the scaffolds that 
had CDI activation was statistically significant though (p<0.01 in both cases).   
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Figure 4.6a:  DNA content as a function of BMP-2 immobilization method 
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Figure 4.6b:  AP activity as a function of BMP-2 immobilization method 
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5 DISCUSSION 
5.1 Microsphere Characterization using Particle Size Testing 
 After results indicated that scaffolds made with larger diameter microspheres 
retained more heparin, particle size testing was done to determine the range of diameters 
produced for microspheres prepared using the homogenizer and for microspheres made 
with the magnetic stirrer at 450 rpm.  Microspheres that were prepared using the 
magnetic stirrer at 600 rpm did not undergo particle size testing because SEM pictures 
revealed that those microspheres were too small to be effective.  The method using the 
homogenizer to prepare microspheres resulted in diameters that were too small to make 
scaffolds with effective pore sizes (greater than 100 µm).  Therefore, the use of the 
homogenizer was discontinued.  Reducing the rotation speed of the magnetic stirrer to 
450 rpm instead of 600 rpm resulted in microsphere diameters approximately 100 
microns larger than the spheres produced with the homogenizer.   
 Borden, et al. used PLGA with an 85/15 ratio and a molecular weight (MW) of 
420 kDa to make microspheres that were used for porous PLGA construction in one 
experiment.  In another experiment, the same group used 50/50 PLGA with a MW of 50 
kDa, a 75/25 ratio with MW of 92 kDa, and 85/15 ratios with 420 kDa and 92 kDa to 
make microspheres for use in scaffold preparation.[2, 7]  They were able to produce 
scaffolds made with microspheres that had diameters of 600-710 µm, 355-425 µm, and 
212-250 µm for the 85/15 & 420 KDa PLGA.  The microsphere sizes were all between 
425 and 610 µm for the second experiment they conducted.  This was in contrast to the 
scaffolds made with our microspheres that had diameters of just over 150 µm.  For this 
thesis research, there were not enough microspheres larger than 150 µm in diameter to 
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make enough scaffolds to be useful for experimental purposes.  This suggests that higher 
molecular weight PLGA chains with a greater ratio of lactic acid to glycolic acid could be 
more appropriate for producing larger microspheres.  For the current work, reducing the 
spinning speed from 600 rpm to 450 rpm partially compensated for the low molecular 
weight PLGA that was used.   
5.2 Scaffold Characterization 
5.2.1 General Scaffold Characterization 
 The pictures of the scaffolds in Figures 4.2.1 showed that all the scaffolds 
produced were generally the same size and shape.  They were not identical though and 
certainly some of the error in the results was due to the variations in size from scaffold to 
scaffold.  For instance, smaller scaffolds had less surface area available for spacer and 
growth factor attachment than larger scaffolds.  Even a small difference in surface area 
led to a much larger difference at the molecular level with respect to biomolecule 
attachment, and accounted for some of the variations seen in the results.   
5.2.2 Mercury Intrusion Porisometry  
 The MIP data for the scaffolds made using 25 mg of 50-150 µm diameter 
scaffolds indicated an overall porosity that was less than that of cancellous or trabecular 
bone (47% versus approximately 70%).[7]  The mean pore diameter, depending upon the 
calculation method (Micrometrics software), was between 30 and 41 µm.  It is generally 
agreed upon that for adequate penetration of cells and the resulting acceptable integration 
of the material with the host tissue, the pore diameter should be at least 100 µm in 
diameter.[7]  The mean diameter of pores in these scaffolds were on the low end of the 
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trabecular bone porosity range and were well below the typical pore diameter that is 
considered suitable for supporting cell growth.  However, based on MIP data and SEM 
images there were pore sizes that were much larger than the mean diameter and therefore 
in agreement with the generally accepted 100 µm diameter minimum diameter for cell 
and tissue penetration.  Also, our objective was not to make scaffolds that completely 
mimicked trabecular bone and there are results that will be discussed below that suggest 
scaffolds with lower porosity than trabecular bone may be acceptable for integration of 
the material into the native bone tissue.  Nonetheless, it was decided to use the greater 
than 150 µm diameter microspheres for scaffold fabrication based on the MIP data 
combined with the information obtained from the SEM images.   
 MIP data was not available for the scaffolds made with the larger spheres.  
However, it was expected that MIP data would show significantly higher porosity and 
larger mean and median pores sizes when compared to scaffolds made with microspheres 
less than 150 µm in diameter.  This assumption was based on SEM comparisons between 
scaffolds made with small diameter microspheres and scaffolds made with large diameter 
microspheres.   
 Borden, et al. fabricated scaffolds with 600-710 µm diameters using the sintered 
microsphere approach that had median pore sizes of 210 µm and 35% porosity.  Although 
their scaffold porosity was low in comparison to trabecular bone, their results showed 
acceptable penetration of cells into the scaffolds.  Other groups that used the gas-
foaming/salt-leaching or solution-casting/salt-leaching methods produced scaffolds with 
average pore sizes of approximately 50-200 µm and > 85 % porosity.[18-20, 66]  The 
studies that looked at cell growth and proliferation reported positive results with those 
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pore sizes and porosity.[18-20]  This suggests that scaffold porosity might not be the 
deciding factor when predicting the success of cellular proliferation on and in a 
biomaterial.  It also further supports the use of PLGA as an effective material for eliciting 
a desired cellular response.   
5.2.3 Scaffold Characterization Using SEM  
 Figures 4.2.3a and 4.2.3c both show the cross-sections of scaffolds at a similar 
magnification.  The scaffolds made with larger diameter microspheres (Figure 4.2.3c) 
showed greater porosity with many pores being well over 200 µm in diameter when 
compared to the scaffolds made with the smaller microspheres that had only a few pores 
with diameters over 100µm (Figure 4.2.3a).  Results from the previously mentioned 
studies where porosity was greater than 85% and the pore sizes were in the 100-200 µm 
range suggest that the scaffolds made with larger diameter microspheres would be more 
appropriate for supporting cell growth.[18-20]  This information provided further support 
for abandoning the fabrication of scaffolds made with less than 150 µm diameter 
microspheres.   
 SEM images of the surface of scaffolds are shown in Figures 4.2.3b and 4.2.3d.  
These pictures, illustrate that there was little porosity on the scaffolds made with smaller 
microspheres (Figure 4.2.3b) and that the larger microsphere scaffolds have larger pore 
sizes and increased porosity (Figure 4.2.3d).  The SEM image of the cross-section of the 
large microsphere scaffolds also suggests that adequate porosity exists throughout the 
scaffold, further supporting the premise that these scaffolds would be well suited for cell 
infiltration.   
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 It is important to note that in the scaffolds made with the larger sphere size, not all 
the microspheres were greater than 150 µm in diameter.  In some cases there appeared to 
be aggregates of small microspheres that were greater than 150 µm in diameter.  It was 
likely that these aggregates formed before the sieving process since the smaller 
microspheres would be removed at that time.  That means they could have formed either 
during the lyophilization process or during the drying process that occured when the 
microspheres were being recovered but before they were placed in the -70°C freezer.  
Regardless of the formation of these aggregates, characterization of the scaffolds made 
with >150 µm diameter microspheres (or in some cases, aggregates that are >150 µm in 
diameter) indicated they were well suited for integration with the host bone tissue.  
Additional studies are needed to examine the effects of reducing the formation of the 
aggregates and increasing the yield of larger microspheres.   
5.2.4 Mechanical Testing 
 While reports vary somewhat, the compressive strength of cortical and cancellous 
bone is typically 120-150 MPa and 10-50 MPa, respectively.[67, 68]  Reports for 
Young's modulus of cortical and cancellous bone also vary somewhat, but are near 15-30 
GPa for cortical bone and between 0.5-1.0 GPa for cancellous bone.[8, 67, 68]  Results 
from mechanical testing done on the PLGA scaffolds fabricated in this experiment 
indicated they would be weak when compared to both cortical and cancellous bone.  
However, these scaffolds were not designed to replace the natural bone, rather they were 
made to fill the defect site, and then degrade as they induced new bone formation into 
that site.  To do this, the scaffolds need to be osteoinductive and able to provide structural 
support for cell attachment and growth.   
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 One study that fabricated scaffolds for cell growth determined that their scaffolds 
had a compressive strength of approximately 0.2 MPa with a modulus at ~ 3.9 MPa.[18]  
These scaffolds had a porosity of about 90%, were manufactured using a particulate 
leaching method, and were shown to support fibroblast cell growth.  Another study that 
fabricated scaffolds using the sintered microsphere approach reported a compressive 
modulus of 232 MPa for scaffolds with 35% porosity.[7]  This study also reported 
osteoblast growth on and into their scaffolds.   
 Comparing the mechanical properties of the two previously mentioned studies to 
those reported in the results section (Table 4.2.4) suggests that our scaffolds are 
mechanically adequate and able to support cell growth.  However, as mentioned before 
the primary purpose of the scaffolds designed for this project was to fill the defect site 
and then to induce the formation of native bone tissue into that site.   
5.3 Spacer Immobilization 
 All the surface modifications were made with the purpose of improving the bone 
regeneration capacity of the PLGA scaffolds.  The initial efforts made in the surface 
modification process involved the attachment of spacers, either hydrazides or heparin, 
then the quantification of those spacers.  These spacers were then used as the attachment 
points for the BMP-2 that was immobilized.   
 Quantification of the spacer molecules was difficult, regardless of whether the 
spacer was a dihydrazide or heparin.  The reasons will be discussed below, but the 
problems with quantification also made determining the optimal surface density of 
spacers and optimal spacer length even more difficult to accomplish.  
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5.3.1 Dihydrazide Immobilizaton 
 The first efforts to quantify spacers, given the same dihydrazide type (AAD) and 
different initial concentration, were made on PLGA coated glass test tubes using TNBS 
as the method for detection and quantification.  The purpose of this particular experiment 
was to determine how effective it would be to control the surface density of the 
dihydrazides by measuring the total amount of hydrazide molecules retained and by 
determining the amount of molecules per unit surface area.  The results suggested that 
higher initial starting amounts of AAD do result in more AAD retained on the surface.  
However, the results were not statistically significant.   
 There are a couple of potential reasons for the differences not being statistically 
significant.  First, the TNBS assay was deemed to lack the sensitivity to give a reliable 
count of the hydrazide molecules at that low of a concentration.  The absorbance values 
obtained for the samples were typically on the low end of the TNBS standard curve.  
Also, this portion of the TNBS standard curve was associated with the highest degree of 
uncertainty which was likely due to the small numbers of molecules at the low end of the 
curve (~1015) and the corresponding inconsistent absorbance values obtained using TNBS 
for those numbers of molecules.   
 Another potential source of the large error range was the PLGA surface itself.  It 
was difficult to consistently reproduce the exact surface area regardless of whether it was 
PLGA-coated test tubes or PLGA scaffolds.  Also, the number of dihydrazide molecules 
that were attached was a function of the amount of carboxyl groups from the PLGA 
chains that were available in a given area.  Assuming that the height of the PLGA in the 
test tubes was 4.0 ± 0.25 mm, there could be a difference of 18 million µm2 in surface 
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area from test tube to test tube.  It is possible that this potential difference in surface area 
could lead to a large difference in the amount of carboxyl groups between different test 
tubes.  The differences in the surface area from test tube to test tube likely accounted for 
the majority of the uncertainty and the statistical insignificance associated with the 
results.   
 Efforts were also made to determine dihydrazide retention on the PLGA-coated 
test tubes as a function of the dihydrazide type.  Alexa 350 was used to quantify the 
dihydrazides, because of the concern for the sensitivity of the TNBS.  The results 
indicated that the largest dihydrazide, the C10 or sebacic dihydrazide, had superior 
retention in comparison to the smaller dihydrazides given the same initial starting 
concentration.  One possibility for the results indicating increased retention with the C10 
dihydrazide may be related to steric hinderance.  There may have been enough steric 
hindrance from the surrounding polymer on the smaller dihydrazides to cause 
interference with the binding of Alexa 350 to the free hydrazide portion of the 
immobilized dihydrazides.  Therefore, if the smaller dihydrazides bound in the same 
percentages as the C10 dihydrazide, they may not have been detected because the free 
hydrazide end was hindered from binding with the Alexa 350 in solution.  Another 
possibility was that the longer length of the C10 dihydrazides may have led to a more 
favorable alignment of the free hydrazide functional groups for binding with the Alexa.   
 Because TNBS was initially used to quantify AAD for the surface density 
experiment, a similar experiment was designed where Alexa 350 was used to quantify 
AAD retention on PLGA coated test tubes.  This time the initial starting concentrations 
were less than before (1014, 1013, and 1012 versus ~ 1020 molecules).  The main reason for 
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decreasing the initial starting concentration was that there was a very large excess of 
dihydrazide molecules when compared to what could theoretically be expected to be in a 
given area with the initial concentrations where they were.  It was also convenient for 
comparison purposes to have 10-fold increases in the amount of initial starting 
concentrations of molecules.  The results with this test also implied that higher initial 
starting concentrations led to more molecules retained, which further indicates that 
controlling the surface density of spacer molecules on the biomaterial surface is feasible.  
However, the only statistically significant difference was between the starting 
concentrations containing 1014 and 1012 molecules.  Again, this was due to the large 
standard deviations, which were likely due to the variations in the PLGA surface area.   
5.3.2 Dihydrazides and Heparin 
 Numerous studies have shown that heparin has a strong affinity for BMP-2 and 
generally improves the bioactivity.[15, 35, 45, 61, 69]  Using this knowledge, efforts 
were made to link heparin with dihydrazides that were immobilized on the PLGA 
surface.  This was done by oxidizing the diols on heparin to aldehydes so that they would 
react with the hydrazide functional groups to create a hydrazone linkage.  The Blyscan 
assay was used to quantify the heparin that was immobilized in this manner, however it 
was not successful because the PLGA masked the signal that the heparin would have 
produced.  The method that uses toluidine blue to detect heparin was not used to detect 
heparin bound to the immobilized dihydrazides on the biomaterial surface.  This was 
primarily because it was determined that it would be more efficient to attach heparin 
directly to the PLGA surface.   
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5.3.3 Heparin 
 Results from the direct attachment of heparin to the PLGA scaffolds without the 
use of dihydrazides confirmed that the dihydrazides were not actually needed for heparin 
attachment.  The main purpose of this experiment was to confirm that the use of CDI to 
covalently attach heparin to the scaffolds would result in more heparin immobilized on 
the surface than would random adsorption of heparin. 
 The results also indicated that scaffolds made with larger microspheres (>150 µm 
in diameter), given the same molecular weight of PLGA and the same initial 
concentration of heparin, retained more heparin on the surface than did scaffolds made 
with smaller microspheres.  The rationale for this was that the scaffolds made with larger 
microspheres conceivably had more surface area than did the small microsphere 
scaffolds.  These results combined with the pore sizes and porosity associated with the 
scaffolds made with larger microspheres further supported the premise that scaffolds 
made with the larger microspheres had greater potential to be used as a tissue engineering 
tool for inducing bone regeneration.   
 One other notable observation from the results was that scaffolds made with 
higher molecular weight PLGA showed better heparin retention than did scaffolds made 
with smaller molecular weight when both were made with greater than 150 µm 
microspheres.  The suspected reason for this was that the larger molecular weight PLGA 
would more readily form larger microspheres and therefore produce more microspheres 
with larger mean diameters.  Larger diameter microspheres would lead to scaffolds with 
increased surface area which could result in more biomolecules attached to the 
biomaterials surface.  There is some support for this theory based on the results by 
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Borden, et al.[2, 6, 7]  They used a variety of PLGA with different ratios of PGA to PLA 
with molecular weights ranging from 50 kDa to 420 kDa to conduct their experiments.  In 
comparison, the PLGA used for this thesis was approximately 9-23 kDa.  Their results 
showed the formation of microspheres with diameters ranging from 212 µm to 710 µm 
and the ability for osteoblast penetration into their scaffolds.  The objective of this thesis 
did not involve the examination of osteoblast penetration, so a direct comparison cannot 
be made.  However, they achieve larger diameter microspheres using larger MW PLGA.   
 Other studies have looked at the ability of heparin to enhance the effects of BMP-
2 on different cell types.  Experiments by Kamijo, et al. showed that heparin enhanced 
the effect of BMP-2 on C2C12 myoblasts in vitro and in vivo.[35, 45]  However, these 
studies used heparin in solution at concentrations up to 30 µg/ml, instead of binding it to 
the surface of the biomaterial.   
 In other studies heparin was immobilized onto porous PLGA microspheres and to 
PLGA scaffolds.[16, 17]  Amino-terminated PLGA was used to get 95.8 pmole (1.15 µg) 
of heparin/mg of microspheres.[16]  Assuming a microgram of microspheres was 
equivalent to a microgram of scaffolds; this would have resulted in 63 µg of heparin per 
scaffold at a mass of 55 mg per PLGA scaffold.  However, when using the same amino-
terminated PLGA to make scaffolds (10 mm diameter by 2 mm thickness, but no 
indication of the mass of scaffolds or of the porosity), only 36.9 pmole (0.443 µg) of 
heparin per scaffold was able to be immobilized.[17]  This was less than 0.3% of the 
heparin initially loaded onto the scaffolds.  In comparison, using carboxyl-terminated 
PLGA scaffolds (from this thesis experiment) with CDI to immobilize heparin on the 
PLGA surface resulted in 3.2% of the initial heparin amount being retained on the 
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scaffolds (16.03 µg of heparin/per scaffold that is approximately 4.8 mm diameter by 5.8 
mm high).  Kim, et al. also used amine terminated PLGA scaffolds to immobilize 
heparin, but had an efficiency of 2.5%.[15]   
5.4 BMP-2 Immobilization  
 As expected based on other published research [15, 35], BMP-2 was immobilized 
in greater quantities with scaffolds that had heparin covalently attached to the PLGA 
scaffolds using CDI than to any of the other BMP-2 attachment methods.  However, it is 
not enough to have BMP-2 immobilized in greater quantities.  If the immobilized protein 
is not oriented in a manner that is preferential for cell binding then the volume of BMP-2 
attached is irrelevant because its ability to interact with cell surface receptors would be 
greatly reduced.  Regardless, other studies have examined BMP-2 attachment on various 
scaffold types to verify the effects of BMP-2 on bone formation.  It was worth comparing 
those results to the results obtained in this thesis research.   
 Kamakura, et al. randomly adsorbed 10 µg and 1 µg of rhBMP-2 to synthetic 
calcium phosphate granules that were used to form scaffolds for an in vivo experiment 
testing the effectiveness of their scaffolds for improving bone formation in critical size 
defects of rat calvarium.[70]  There was no statistical difference in the effectiveness of 
the BMP-2 loaded scaffolds, but both cases were better at inducing bone growth than 
calcium phosphate scaffolds without BMP-2 loaded.   
 In a study by Boyan, et al., PLGA particles with adsorbed BMP-2 were compared 
to demineralized freeze-dried bone allografts for bone formation at intramuscular sites in 
mice.[71]  Here, 5 µg and 20 µg of BMP-2 loaded in PLGA particles showed 3.5-fold 
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and 4.4-fold increases in new bone area, respectively, when compared to the 
demineralized freeze-dried bone allograft.   
 Welch, et al. looked at absorbable collagen sponges with 0.86 mg of BMP-2 
loaded into them to study the healing of critical size defects in large animal tibial 
fractures.[46]  Again, the BMP-2 loaded vehicle resulted in enhanced bone volume in 
comparison to controls without BMP-2.   
 These experiments demonstrate that amounts as low as a microgram of BMP-2 
are effective for promoting bone formation which suggests that the amounts of BMP-2 
immobilized on our scaffolds should be sufficient to induce bone formation.  However, 
none of the previously mentioned studies actually attached the BMP-2 on the biomaterial 
surface in any manner other than adsorption, and none addressed the issue of BMP-2 
orientation.   
 Jeon, et al. investigated heparin loaded PLGA scaffolds as a method of providing 
a sustained delivery of BMP-2 for inducing ectopic bone formation.  This study showed 
that scaffolds with heparin chemically attached to the scaffold surface prolonged the 
activity of BMP-2 in vitro.[15]  However, no attempt was made to determine the 
orientation of the BMP-2 that was immobilized.   
5.5 BMP-2 Orientation 
 The quantities of loaded or immobilized BMP-2 are important.  However, for this 
research, efforts were also made to control and detect the orientation of the immobilized 
BMP-2 using heparin that was chemically attached and randomly adsorbed to PLGA 
scaffolds.  Efforts to probe for the orientation of the immobilized BMP-2 involved the 
use of antibodies for the N- and C- terminus of BMP-2.  These efforts were not without 
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difficulties.  First, BMP-2 is a homodimer consisting of two, 114 amino acid sequence 
BMP-2 monomers.  This suggests that there are two N- and C-terminals per BMP-2 
molecule.  Therefore, if only one of the BMP-2 N-terminals was bound to heparin, the 
other N-terminal was still available to bind with the antibody.  Another difficulty 
associated with probing for orientation using the C-terminus antibody was that the C-
terminus is buried somewhat within the structure of the molecule (Figure 2.3a) and will 
therefore be sterically hindered from binding with the C-terminus antibody.   
 With regards to the results of the antibody tests, the first thing noticed was the 
large error bars associated with high standard deviations.  Not surprisingly, none of the 
differences were consider statistically significant.  Some of the error was due to the 
inherent variations in the different scaffolds.  Another source of the uncertainty was 
associated with steric hindrance affects on the antibodies used to probe for orientation of 
the BMP-2 molecule.   
 Assuming that the heparin does bind to the N-terminus region of BMP-2 [48], N-
terminal antibody probes for BMP-2 should be more effective on scaffolds without 
heparin loaded and the C-terminal antibody probes should be more effective on scaffolds 
with heparin.  Interestingly, neither the absolute values of absorbance nor the ratios of 
absorbance to BMP-2 mass supported this expectation.  Again, the suspected reason for 
these results comes from the difficulties using antibodies and the variations in the 
scaffolds.  However, the use of antibodies to probe for the conformation of the BMP-2 
immobilized on the heparin loaded scaffolds did confirm that there was BMP-2 present.  
Also, the BMP-2 epitopes are still able to bind with the cell receptors and the 
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immobilization of BMP-2 using heparin did not alter the conformation such that the 
BMP-2 antibodies were ineffective at detecting BMP-2.   
5.6 C3H10T1/2 Cells and BMP-2 Loaded Scaffolds 
 The results from the DNA assay (Table 4.6 and Figure 4.6a) seem to indicate that 
PLGA scaffolds by themselves (group 5) can support cell growth and proliferation.  This 
was based on the DNA assay results that indicated more cell growth on blank PLGA 
scaffolds than on scaffolds with CDI activation.  The results also indicated more cellular 
proliferation on the scaffolds that did not have CDI activation (groups 1 & 2) regardless 
of the presence of heparin.  Based on the inverse relationship between proliferation and 
differentiation of osteoblastic cells,[72, 73] this was an indication that cells immobilized 
on the scaffolds with CDI activation (groups 3 & 4) were undergoing differentiation into 
the osteoblast phenotype more than they were proliferating on the scaffolds.   
 The results of the AP assay (Table 4.6 and Figure 4.6b) suggest that the oriented 
attachment of BMP-2 using heparin covalently bound to the scaffolds via CDI (group 3) 
does lead to more C3H10T1/2 differentiation than does random attachment of BMP-2.  
This was based on the differences in activity when comparing the oriented BMP-2 
scaffolds from group 3 to those scaffolds that had BMP-2 randomly adsorbed without the 
use of heparin or CDI activation (group 2).   
Another comparison that looked at the effectiveness of the different heparin 
immobilization methods on cellular differentiation suggests that BMP-2 bound to 
covalently attached heparin (group 3) was more effective at inducing C3H10T1/2 
differentiation than does BMP-2 bound with the simple adsorption of heparin (group 1).  
The reason for this was likely due to the amount of BMP-2 immobilized on each scaffold 
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type.  For instance, the amount of BMP-2 retained on scaffolds with covalently attached 
heparin was about three times greater than the amount of BMP-2 retained on scaffolds 
with adsorbed heparin (Figure 4.4).  Similarly, the amount of AP activity from scaffolds 
with covalently attached heparin (group 3) was about three times greater than the activity 
of scaffolds with randomly attached heparin (group 1).  The implication here was that 
heparin will orient BMP-2 in a preferred manner, but more heparin and therefore more 
oriented BMP-2 will be retained with covalent heparin attachment using CDI.   
An argument can be made against the effectiveness of the covalently attached 
heparin method when compared to adsorbed heparin attachment though.  The activity of 
each of the different BMP-2 immobilization methods was normalized by the amount of 
BMP-2 retained from a previous experiment (Table 4.6).  The normalized AP activities 
were similar (16.0 for group 1 and 15.4 for group 3) and indicated that there was little 
difference in the amount of activity per µg of BMP-2 immobilized.   
The other comparison of interest was the AP activity from scaffolds with 
covalently attached heparin using CDI (group 3) to scaffolds that had CDI activation 
without heparin (group 4).  The activity from both cases was not statistically significant 
when compared to each other.  These results suggest that CDI activation of the carboxyl 
groups can be as effective at immobilizing BMP-2 in a manner that promotes cell 
differentiation as can the oriented immobilization of BMP-2 using covalently attached 
heparin.  However, the standard deviation was almost 50% with scaffolds that were CDI 
activated without heparin (group 4) compared to only ~13% with scaffolds that had CDI 
(covalently) attached heparin (group 3).  This implies that while CDI activation alone can 
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lead to effective immobilization of BMP-2, it cannot do it as consistently as the scaffolds 
with covalently attached heparin.   
Another observation was that about a third more BMP-2 was immobilized on 
covalently attached heparin scaffolds (group 3) than on CDI activated scaffolds with no 
heparin attachment (group 4) (Figure 4.4).  Based on this observation, a comparison of 
the normalized AP activities between groups 3 and 4 was made.  That comparison 
indicated that group 4 scaffolds actually induced more (23.9 versus 15.4 for normalized 
AP activity) differentiation of C3H10T1/2 cells than did the oriented BMP-2 scaffolds 
from group 3.  This suggests that the CDI only scaffolds (group 4) had more activity with 
a smaller amount of BMP-2 and provides an argument against the effectiveness of 
orientation.  However, there was nearly 50 % error associated with the group 4 scaffolds 
and neither the differences in the amounts of BMP-2 retained nor the AP activity 
associated with these two types of scaffolds was statistically significant.  Also, before it 
can be concluded that oriented BMP-2 immobilization was no more effective at inducing 
osteoprogenitor cell differentiation than random immobilization, one must also consider 
the other effects of heparin.  As mentioned in the background section, heparin has been 
shown to have an affinity for the N-terminus of BMP-2 which can be used to immobilize 
BMP-2 in a preferred orientation.[38, 48, 54]  In addition, heparin has also been shown to 
prevent BMP-2 inhibitors such as noggin from binding with BMP-2 thereby increasing 
the activity of the immobilized BMP-2.[15, 45, 49, 62]  The C3H10T1/2 in vitro system 
used for this research did not allow investigation of these effects.  Regardless, this 
information suggests that while the immobilization of BMP-2 directly onto PLGA 
scaffolds may be as effective as at inducing differentiation in vitro than oriented 
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immobilization using heparin, it may not be effective in in vivo studies or even in in vitro 
studies with BMP-2 inhibitors present.   
Results similar to those obtained in this research were obtained by another group.  
An in vitro study by Kim et al. showed that BMP-2 loaded onto heparin-conjugated 
PLGA scaffolds increased AP activity in osteoblasts for two weeks compared to only a 
transient three day increase with a decrease in activity thereafter for BMP-2 loaded onto 
unmodified (without heparin) PLGA scaffolds.[15]  They reported that 19% of the BMP-
2 was released from the heparin-conjugated scaffolds after 24 hours, whereas nearly all of 
the BMP-2 loaded onto the unmodified scaffolds was gone within 4 hours.  A subsequent 
in vivo study also demonstrated more ectopic bone formation with BMP-2 loaded onto 
heparin-conjugated scaffolds than either BMP-2 loaded on unmodified scaffolds or 
heparin-conjugated scaffolds without the presence of BMP-2.[15]  This further supports 
the use of heparin as an effective immobilization method for BMP-2.  There was no 
mention in that study of determining the actual orientation of the BMP-2.  Their goal was 
purely to determine if BMP-2 bound to covalently attached heparin produced more 
differentiation than BMP-2 loaded scaffolds without heparin.   
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6 CONCLUSION 
 The results indicated that PLGA scaffolds can be effectively constructed using 
PLGA microspheres.  While these scaffolds were fabricated to be cylinders, the potential 
exists for the scaffolds to be shaped as desired to fit into any defect site.   
 The ability to chemically modify the surface of the scaffolds for the attachment of 
spacers was also demonstrated with the addition of both dihydrazides and heparin, 
although only heparin was used to attach BMP-2.  The orientation of BMP-2 along with 
its distance from the biomaterial surface and its surface density has the potential to be 
controlled with the use of spacers.  Also, the conclusion can be made that covalent 
heparin attachment using CDI chemistry will result in more heparin being retained and 
also more BMP-2 being immobilized on the scaffold surface.   
 With regards to the cellular activity, the scaffolds that had oriented BMP-2 
attachment using covalently bound heparin demonstrated more activity on C3H10T1/2 
cells than did both scaffolds with random adsorption of BMP-2 and scaffolds that had 
heparin simply adsorbed.  Based on these results, it can be concluded that oriented 
immobilization can lead to increased cellular differentiation.   
 There was similar AP activity with both types of CDI activated scaffolds, that is 
with heparin as a spacer and with BMP-2 directly attached to the polymer.  However, the 
scaffolds with randomly immobilized BMP-2 had much larger error associated with them 
than did the scaffolds that had BMP-2 oriented using covalently attached heparin.  The 
conclusion here was that BMP-2 immobilized using CDI activation alone can lead to 
effective, but inconsistent, differentiation of C3H10T1/2 cells in vitro when compared to 
oriented immobilization using covalently bound heparin.  It was also speculated that in 
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vivo studies would show that oriented immobilization of BMP-2 using covalent heparin 
attachment would show more effective osteoprogenitor differentiation than the random 
immobilization of BMP-2 (no heparin) scaffolds.  This was due to the ability of heparin 
to prevent BMP-2 inhibitors from downregulating BMP-2.  Future studies involving 
implantation of scaffolds in animals will be needed to further resolve this issue.   
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